Published in
The New England Journal of Medicine, NEJM Group
Content
Christine N. Duncan, Jacob R. Bledsoe, Bartosz Grzywacz, Amy Beckman, Melissa Bonner, Florian S. Eichler, Jörn-Sven Kühl, Marian H. Harris, Sarah Slauson, Richard A. Colvin, Vinod K. Prasad, Gerald F. Downey, Francis J. Pierciey, Melissa A. Kinney, Marianna Foos, Ankit Lodaya, Nicole Floro, Geoffrey Parsons, Andrew C. Dietz, Ashish O. Gupta, Paul J. Orchard, Himal L. Thakar, and David A. Williams From Dana–Farber/Boston Children’s Cancer and Blood Disorders Center, Harvard Medical School (C.N.D., D.A.W.), the Department of Pathology, Boston Children’s Hospital (J.R.B., M.H.H.), and Massachusetts General Hospital and Harvard Medical School (F.S.E.) — all in Boston; the Department of Laboratory Medicine and Pathology, University of Minnesota Medical Center (B.G., A.B.), and the Division of Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota (A.O.G., P.J.O.) — both in Minneapolis; Bluebird Bio, Somerville, MA (M.B., S.S., R.A.C., V.K.P., G.F.D., F.J.P., M.A.K., M.F., A.L., N.F., G.P., A.C.D., H.L.T.); the Department of Pediatric Oncology, Hematology and Hemostaseology, Leipzig University Hospital, Leipzig, Germany (J.-S.K.); and the Division of Pediatric Transplant and Cellular Therapy, Duke University School of Medicine, Durham, NC (V.K.P.).
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 55
- Comments 0